| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cefotetan targets penicillin-binding proteins (PBPs), which are enzymes essential for bacterial cell wall synthesis. By binding to these PBPs, it inhibits the transpeptidase and carboxypeptidase activities required for peptidoglycan cross-linking, leading to a weakened cell wall and bacterial cell lysis. Its cephamycin structure confers high resistance to β-lactamase enzymes, making it effective against many β-lactamase-producing bacteria.
|
|---|---|
| ln Vitro |
In vitro, Cefotetan exhibits potent antimicrobial activity against a broad spectrum of bacteria. Its activity is assessed by determining the minimum inhibitory concentration (MIC) against various bacterial strains. It is effective against many Gram-negative and Gram-positive organisms, including anaerobes. Its stability against β-lactamases is a key feature of its activity.
|
| ln Vivo |
In vivo, Cefotetan is used to treat a variety of bacterial infections and for surgical prophylaxis. Its broad-spectrum activity and resistance to β-lactamases make it a valuable antibiotic for treating serious infections. It is administered parenterally and is well-distributed in tissues and body fluids.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Cefotetan are not standard, as it is an antibiotic that targets a cellular process. Its mechanism is studied by measuring its binding affinity to PBPs in membrane preparations.
|
| Cell Assay |
In vitro cell-based assays for Cefotetan use standard microbiological methods, such as broth microdilution and agar diffusion, to determine the MIC against various bacterial strains. Time-kill assays are used to evaluate its bactericidal activity over time.
|
| Animal Protocol |
In vivo animal studies for Cefotetan employ models of bacterial infection, such as murine sepsis or pneumonia models. The compound is administered, and its efficacy is measured by the reduction in bacterial load, survival rates, or clinical signs of infection. Pharmacokinetic studies are also performed to characterize its absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Cefotetan has a molecular weight of 575.62 g/mol and a molecular formula of C₁₇H₁₇N₇O₈S₄. It is a white to light yellow powder to crystal. It is a semi-synthetic cephamycin antibiotic. The compound should be stored under appropriate conditions, typically at room temperature, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Cefotetan has been discontinued in the United States. Current information indicates that cefotetan is present in low concentrations in breast milk and is not expected to have adverse effects on breastfed infants. There have been reports that cephalosporins occasionally disrupt the gut microbiota of infants, leading to diarrhea or thrush, but these effects have not been fully assessed. Cefotetan is safe for use by breastfeeding women. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Breastfeeding and Breast Milk No published information found as of the revision date. Cefotetan is generally well-tolerated, but side effects can include gastrointestinal disturbances, hypersensitivity reactions, and effects on blood coagulation (due to its N-methylthiotetrazole side chain). It is contraindicated in patients with a history of hypersensitivity to cephalosporins. |
| References |
Immunologic evaluation of patients with cefotetan-induced anaphylaxis. Allergy Asthma Immunol Res. 2015 May;7(3):301-3.
|
| Additional Infomation |
Cefotetan is a semi-synthetic second-generation cephalosporin antibiotic. Its cephalosporin skeleton has [(1-methyl-1H-tetrazol-5-yl)thio]methyl, methoxy, and {[4-(2-amino-1-carboxy-2-oxoethylene)-1,3-dithionecyclobutane-2-yl]carbonyl}amino groups attached to the 3, 7α, and 7β positions, respectively. It is resistant to many β-lactamases and is effective against a variety of aerobic and anaerobic Gram-positive and Gram-negative bacteria. It is an antibacterial drug. It is the conjugate acid of cefotetan (2-). Cefotetan is a cephalosporin antibiotic. The effects of cefotetan in bovine (Bos taurus) have been reported, and relevant data are available. Cefotetan is a semi-synthetic cephalosporin antibiotic that can be administered intravenously or intramuscularly. This drug exhibits high resistance to various β-lactamases and is effective against a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria.
See also: Cefotetan (note moved to). Cefotetan is a second-generation cephamycin antibiotic used to treat a variety of bacterial infections and for surgical prophylaxis. It is highly resistant to β-lactamases. It is not a research compound but an approved therapeutic agent. |
| Molecular Formula |
C17H17N7O8S4
|
|---|---|
| Molecular Weight |
575.6190
|
| Exact Mass |
575.002
|
| Elemental Analysis |
C, 35.47; H, 2.98; N, 17.03; O, 22.24; S, 22.28
|
| CAS # |
69712-56-7
|
| Related CAS # |
Cefotetan disodium;74356-00-6
|
| PubChem CID |
53025
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Melting Point |
173-178ºC (dec.)
|
| Index of Refraction |
1.921
|
| LogP |
2.34
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
36
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
S1C([H])([H])C(C([H])([H])SC2=NN=NN2C([H])([H])[H])=C(C(=O)O[H])N2C([C@]([C@@]12[H])(N([H])C(C1([H])S/C(=C(/C(=O)O[H])\C(N([H])[H])=O)/S1)=O)OC([H])([H])[H])=O
|
| InChi Key |
SRZNHPXWXCNNDU-RHBCBLIFSA-N
|
| InChi Code |
InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/t13?,15-,17+/m1/s1
|
| Chemical Name |
(6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| Synonyms |
cefotetan; ICI156834; ICI-156834; YM-09330; YM 09330; 69712-56-7; Cefotetanum; ICI 156834; YM09330; Cefotan; C17H17N7O8S4;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~434.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7373 mL | 8.6863 mL | 17.3726 mL | |
| 5 mM | 0.3475 mL | 1.7373 mL | 3.4745 mL | |
| 10 mM | 0.1737 mL | 0.8686 mL | 1.7373 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
